A Randomized, Single Dose, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Single Dose, Orally Administered, Combined Zibotentan/Dapagliflozin in Healthy Participants
Latest Information Update: 06 Mar 2026
At a glance
- Drugs Dapagliflozin/zibotentan (Primary)
- Indications Renal failure
- Focus Pharmacokinetics
- Sponsors AstraZeneca
Most Recent Events
- 03 Mar 2026 Planned End Date changed from 8 Apr 2026 to 13 Apr 2026.
- 03 Mar 2026 Planned primary completion date changed from 8 Apr 2026 to 13 Apr 2026.
- 03 Mar 2026 Status changed from not yet recruiting to recruiting.